ImmuCell Corp (ICCC) company profile

ImmuCell Corporation is an animal health biologics enterprise that develops, produces, and markets products designed to enhance the health, survivability, and performance of newborn dairy and beef calves. Its core offering is the First Defense product line, which uses hyperimmunized bovine colostrum to deliver pathogen-specific antibodies that protect young calves against scours, a severe diarrheal condition caused by bovine coronavirus, rotavirus, and E. coli. The product portfolio includes single-dose boluses, gel formulations, and bulk powder functional feed ingredients marketed as First Defense Technology. In addition, the business supplies a diagnostic tool known as the California Mastitis Test. ImmuCell serves commercial dairy operations, specialized calf ranches, and beef producers, selling its products through a commercial team in partnership with international, national, and regional animal health distributors.

The company concentrates its manufacturing and operational footprint at a single production location. ImmuCell maintains market presence and distribution across the United States and Canada while actively pursuing regulatory clearances and expansion into other international territories. The provided report does not state the specific city or state of the company's headquarters.

Summary of the business section of ImmuCell's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“We currently have 73 employees who are engaged primarily in quality and manufacturing operations, sales and marketing, product development and finance and administration.”